Jansitin Duo (Metformin Hydrochloride, Sitagliptin)

• Jansitin Duo combines metformin and sitagliptin to manage hyperglycemia in type 2 diabetes.
• Type 2 diabetes mellitus: improves overall glycemic control and helps achieve HbA1c targets when used as part of a comprehensive treatment plan.
• Adjunct therapy in patients inadequately controlled on metformin alone: provides additional glucose‑lowering effect to reach therapeutic goals.

• Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby lowering fasting glucose. Sitagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of incretin hormones (GLP‑1 and GIP). The elevated incretins stimulate glucose‑dependent insulin secretion and suppress glucagon release, complementing metformin’s actions to achieve better overall glycemic control. The combined effect reduces both basal and postprandial glucose excursions, supporting achievement of individualized glycemic targets.

Like all antidiabetic agents, Jansitin Duo may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain, or diarrhea.
• Upper respiratory tract infection: mild cold‑like symptoms.
• Headache: transient mild headache.
• Vitamin B12 deficiency: long‑term metformin use may reduce absorption.
• Dizziness: occasional light‑headedness.
• Hypoglycemia (when combined with sulfonylureas or insulin): symptoms of low blood sugar.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening accumulation of lactate, especially in renal impairment.
• Pancreatitis: severe abdominal pain with elevated enzymes.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Jansitin Duo, clinicians should evaluate patient factors and follow safety recommendations.

• Renal function assessment: avoid or adjust dose in moderate to severe renal impairment.
• Lactic acidosis risk: contraindicated in patients with hepatic disease, alcoholism, or conditions predisposing to hypoxia.
• Hypoglycemia monitoring: caution when used with insulin or sulfonylureas.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Drug interactions: review concomitant medications that may affect glucose levels or renal clearance.
• Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Jansitin Duo can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Insulin or sulfonylureas: may cause severe hypoglycemia; dose adjustment required.
• Iodinated contrast media: can precipitate renal dysfunction, increasing risk of metformin‑associated lactic acidosis.
• Cimetidine: may increase sitagliptin plasma concentrations, raising risk of adverse effects.

Moderate Interactions (Monitor Closely)

• Diuretics (loop or thiazide): may affect renal function, necessitating monitoring of metformin clearance.
• Beta‑blockers: may mask hypoglycemia symptoms.
• Rifampin: may reduce sitagliptin levels, potentially decreasing efficacy.